一名感染HIV-1 CRF_AG的患者中出现的雷特格韦耐药性传播情况。
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
作者信息
Boyd Sarita D, Maldarelli Frank, Sereti Irini, Ouedraogo G Laissa, Rehm Catherine A, Boltz Valerie, Shoemaker Diana, Pau Alice K
机构信息
SAIC-Frederick, Inc., MD, USA.
出版信息
Antivir Ther. 2011;16(2):257-61. doi: 10.3851/IMP1749.
Abstract
Here, we describe an HIV-infected patient with pretreatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the ultimate ability to achieve viral suppression. Pretreatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression.
摘要
在此，我们描述了一名对拉替拉韦、核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂和蛋白酶抑制剂存在治疗前耐药性的HIV感染患者，以及最终实现病毒抑制的能力。由于目前认为导致对拉替拉韦耐药的传播性整合酶突变可忽略不计，因此治疗前整合酶耐药性检测并非常规进行。我们建议，对于存在传播性多类药物耐药性的患者，进行治疗前整合酶基因型检测，以便制定最佳的初始治疗方案并增加病毒学抑制的机会。
相似文献
1
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.一名感染HIV-1 CRF_AG的患者中出现的雷特格韦耐药性传播情况。
Antivir Ther. 2011;16(2):257-61. doi: 10.3851/IMP1749.
2
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.Y143 艾滋病毒 1 整合酶突变对拉替拉韦体外和体内耐药性的影响。
Antimicrob Agents Chemother. 2010 Jan;54(1):491-501. doi: 10.1128/AAC.01075-09. Epub 2009 Nov 9.
3
No residual activity of raltegravir after development of 148 complex mutations in vivo.在体内出现148种复合突变后，拉替拉韦无残留活性。
J Int Assoc Physicians AIDS Care (Chic). 2008 Nov-Dec;7(6):281-2. doi: 10.1177/1545109708327489.
4
The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.HIV-1 整合酶基因型强烈预测拉替拉韦的敏感性，但不能预测原发性病毒分离物的病毒适应性。
AIDS. 2010 Jan 2;24(1):17-25. doi: 10.1097/QAD.0b013e328331c81e.
5
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.拉替拉韦治疗失败的经治患者中整合酶抑制剂耐药模式与 HIV-1。
J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12.
6
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.携带可导致非核苷类逆转录酶和整合酶链转移抑制剂耐药突变的 HIV-1 中病毒适应性和药物敏感性的改变。
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
7
Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.HIV-1 遗传背景和 HIV-1 群体大小对拉替拉韦耐药性进化的影响。
Retrovirology. 2018 Jan 5;15(1):1. doi: 10.1186/s12977-017-0384-z.
8
Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.利用超深度测序揭示一名感染HIV-1儿童中对整合酶抑制剂产生多药耐药变异体的选择动态。
J Antimicrob Chemother. 2017 Mar 1;72(3):850-854. doi: 10.1093/jac/dkw507.
9
Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.整合酶耐药性检测在接受过雷特格韦预治疗失败患者的前病毒HIV-1 DNA中的应用价值。
BMC Infect Dis. 2016 May 13;16:197. doi: 10.1186/s12879-016-1545-8.
10
Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.初治和经治的感染B型和非B型HIV-1变异株患者中整合酶抑制剂原发性耐药突变的流行情况。
HIV Clin Trials. 2013 Jan-Feb;14(1):10-6. doi: 10.1310/hct1401-10.
引用本文的文献
1
Do we need routine integrase resistance testing before starting antiretroviral therapy?在开始抗逆转录病毒治疗之前，我们是否需要进行常规的整合酶耐药性检测？
Lancet HIV. 2025 Jun 17. doi: 10.1016/S2352-3018(25)00108-0.
2
Characterization of Human Immunodeficiency Virus-1 Transmission Clusters and Transmitted Drug-Resistant Mutations in Croatia from 2019 to 2022.2019 年至 2022 年克罗地亚人类免疫缺陷病毒-1 传播簇和传播耐药突变的特征。
Viruses. 2023 Dec 11;15(12):2408. doi: 10.3390/v15122408.
3
HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.博茨瓦纳接受基于整合酶链转移抑制剂方案治疗失败的重度治疗患者中的 HIV-1 亚型 C 耐药突变。
Viruses. 2021 Mar 31;13(4):594. doi: 10.3390/v13040594.
4
Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018.2018年中国广东省初治的HIV-1感染成人中整合酶抑制剂相关耐药的缺失情况
Infect Drug Resist. 2020 Dec 8;13:4389-4394. doi: 10.2147/IDR.S284917. eCollection 2020.
5
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.一线基于整合酶抑制剂的抗逆转录病毒治疗的病毒学失败和病毒抑制时间的预测因素。
Clin Infect Dis. 2021 Oct 5;73(7):e2134-e2141. doi: 10.1093/cid/ciaa1614.
6
Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.比较 HIV-1 亚型 C 样本中内部“自制”和商业 ViroSeq 整合酶基因分型检测方法。
PLoS One. 2019 Nov 21;14(11):e0224292. doi: 10.1371/journal.pone.0224292. eCollection 2019.
7
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.整合酶抑制剂耐药突变的监测用于传播的 HIV-1 药物耐药性。
J Antimicrob Chemother. 2020 Jan 1;75(1):170-182. doi: 10.1093/jac/dkz417.
8
Management of Virologic Failure and HIV Drug Resistance.病毒学失败和 HIV 耐药管理。
Infect Dis Clin North Am. 2019 Sep;33(3):707-742. doi: 10.1016/j.idc.2019.05.004. Epub 2019 Jun 27.
9
Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient.煤矿中的金丝雀？初治患者中出现对所有整合酶链转移抑制剂耐药的传播性突变
Open Forum Infect Dis. 2018 Nov 8;5(11):ofy294. doi: 10.1093/ofid/ofy294. eCollection 2018 Nov.
10
[HIV-1 integrase inhibitor resistance among treatment naïve patients in Gran Canaria, 2017].[2017年大加那利岛初治患者中HIV-1整合酶抑制剂耐药情况]
Rev Esp Quimioter. 2018 Oct;31(5):459-460. Epub 2018 Sep 17.
本文引用的文献
1
HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection.HLA-B 等位基因与 HIV 异性传播、病毒载量和艾滋病进展一致相关，但与感染易感性无关。
AIDS. 2010 Jul 31;24(12):1835-40. doi: 10.1097/QAD.0b013e32833c3219.
2
Two independent epidemics of HIV in Maryland.马里兰州的两起独立的 HIV 疫情。
J Acquir Immune Defic Syndr. 2010 Jul;54(3):297-303. doi: 10.1097/QAI.0b013e3181e0c3b3.
3
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.在整合酶治疗初治患者的 HIV-1 准种中发现的次要整合酶耐药突变对整合酶抑制剂的敏感性影响很小或没有。
Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. doi: 10.1128/AAC.01720-09. Epub 2010 May 17.
4
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.体外使用拉替拉韦选择的原发性突变可导致对第一代整合酶抑制剂的敏感性发生大幅度变化，但对具有第二代耐药谱的抑制剂仅有较小的变化倍数。
Virology. 2010 Jul 5;402(2):338-46. doi: 10.1016/j.virol.2010.03.034. Epub 2010 Apr 24.
5
Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.2006 年美国新诊断 HIV-1 感染者中传播相关耐药突变与 HIV-1 亚型的流行情况
AIDS. 2010 May 15;24(8):1203-12. doi: 10.1097/QAD.0b013e3283388742.
6
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.治疗经验丰富的患者在接受基于raltegravir 的挽救治疗方案时的raltegravir 血浆浓度，包括raltegravir 与 maraviroc 联合用药和不联合用药。
Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6.
7
Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.整合酶抑制剂耐药的进化：基于整合酶抑制剂的抗逆转录病毒治疗失败时。
J Acquir Immune Defic Syndr. 2010 Aug;54(4):389-93. doi: 10.1097/QAI.0b013e3181c42ea4.
8
High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.HIV 感染者中整合酶抑制剂初治患者中整合酶 Q148R 少数变异体的高频发生。
AIDS. 2010 Mar 27;24(6):867-73. doi: 10.1097/QAD.0b013e3283367796.
9
Update of the drug resistance mutations in HIV-1: December 2009.2009年12月HIV-1耐药性突变的更新情况
Top HIV Med. 2009 Dec;17(5):138-45.
10
HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.喀麦隆接受或未接受高效抗逆转录病毒治疗的慢性感染个体中 HIV-1 逆转录酶耐药突变。
J Med Virol. 2010 Feb;82(2):187-96. doi: 10.1002/jmv.21677.
Zotero 插件